D
r Glass raises numerous excellent arguments against the use of placebo controls in trials when existing therapies exist. These include: wasting resources or putting participants at risk for no possible gain; the well-being of the patient; and the fiduciary responsibility of the physician.
Two implicit assumptions behind these and other arguments are that all studies will yield correct results, if only they were large enough; and all new drugs that are tested will be both safe and effective. Hence, in randomized controlled trials (RCTs) comparing a new drug to an existing one, all patients will benefit and none will suffer; whereas in a placebocontrolled study, the control patients will be denied any therapy. Were all RCTs perfectly carried out, and if all experimental drugs made it to the market place, this would be a cogent argument. However, in this imperfect world, neither situation occurs. As I indicated previously, many trials fail because they are less-than perfectly designed or executed, even by highly experienced groups. If the results of an active-arm RCT showed no difference, then it is impossible to determine if both drugs were equally effective or equally ineffective. Consequently, the participation of patients in both groups would have been for nought, which indeed would be a waste of resources.
Second, it has been estimated that of the 0.1% of agents that get through preclinical screening and progress to Phase III trials, only 20% ever reach the pharmacy shelves. 1 That means in 80% of trials, the new agent proved ineffective, had too many adverse effects, or both. At the extreme, a number of trials were halted because of increased mortality rates among patients taking the new agents. 2, 3 Consequently, patients taking new drugs are often at risk of unknown adverse drug reactions (ADRs) or even death. As I have pointed out, sample sizes in trials with an active comparator need to enroll considerably more participants than RCTs that use placebo controls, 4 meaning that even more patients are placed at risk.
In all studies, clinicians have a responsibility to explain the risks of participation to all prospective subjects. These include both the possibility of ADRs as well as the chances that the intervention may be ineffective and the patient's state may deteriorate. It is debatable whether it is more ethical to tell people that they may suffer because of adverse reactions or that their condition may worsen. Both require honesty, openness, and a relationship with the patient.
None of this is meant to imply that it is always better to use placebos. In some conditions, such as mild or moderate Alzheimer disease, delaying the start of cholinesterase inhibitors would result in irreversible loss of cognitive functioning. It would clearly be unethical to use placebos under such circumstances. However, when any exacerbation of symptoms is expected to be slow and reversible, then placing fewer patients at risk of adverse events in placebo-controlled trials may balance the risks, resulting in a state of clinical equipoise.
